Sustained conservation of CD4+ T cells in multiprotein triple modality-immunized rhesus macaques after intrarectal challenge with simian immunodeficiency virus
| Autor: | Ulrike Sauermann, Gerhard Hunsmann, Jonathan L. Heeney, Nicole Stolte-Leeb, Christiane Stahl-Hennig, Stephen Norley, Monika Franz, Zahra Fagrouch |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
CD4-Positive T-Lymphocytes
Modified vaccinia Ankara viruses Immunology Genetic Vectors Immunization Secondary Simian Acquired Immunodeficiency Syndrome Vaccinia virus Semliki Forest virus medicine.disease_cause Antibodies Viral Antigen Administration Rectal Virology medicine Vaccines DNA Animals biology SAIDS Vaccines Simian immunodeficiency virus biology.organism_classification Macaca mulatta Semliki forest virus Regimen Immunization biology.protein Molecular Medicine Simian Immunodeficiency Virus Antibody Viral load |
| Zdroj: | Viral immunology. 19(3) |
| ISSN: | 0882-8245 |
| Popis: | As part of a European multicenter study designed to determine the optimal combination and order of a mixed-modality vaccine against acquired immunodeficiency syndrome, rhesus monkeys received a combination of three different vectors, all expressing the same Simian Immunodeficiency Virus (SIV) genes followed by mucosal challenge with highly pathogenic SIV. In the study reported here, animals were primed with DNA followed by one booster immunization with Semliki Forest Virus (SFV) and two immunizations with modified Vaccinia Ankara (MVA). To address the relevance of mucosal immunization, we compared systemic versus a combination of systemic and mucosal antigen application. Although all vaccinees became infected after intrarectal challenge with SIV, most (six of eight) were protected from profound loss of CD4+ cells. In addition, vaccinees showed lower viral loads than did controls (p < 0.05). Overall, these protective effects were more pronounced in those animals whose schedule included immunization via the mucosa. In summary, the vaccine regimen used here achieved one important criterion of efficacy: the suppression of disease development as indicated by conservation of CD4+ cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|